Fujisawa Pharmaceutical Company, Ltd.

Renascience Co., Ltd.

Astellas Pharma Gmbh

Wakunaga Pharmaceutical Co., Ltd.

Kenji Murano

Hiroshi Matsuda

Hiroshi Miyake

Masaaki Matsuo

Keiji Matsuda

Daijiro Hagiwara

Nobukiyo Konishi

Hidenori Ohki

Takashi Manabe

Shinji Shigenaga

David Barrett

Takahiro Matsuya

Kohji Kawabata

Takashi Ogino

Toshio Miyata

Hiroaki Mizuno

Takashi Tojo

Ayako Toda

Nobuyuki Shiraishi

Nagahisa Yamaoka

Satoshi Inoue

Shinya Okuda

Toshio Yamanaka

Kenji Itoh

Norio Hashimoto

Atsushi Kanda

Keiji Misumi

Masaharu Ichihara

Hidehiko Kodama

Atsushi Ohigashi

Kenji Sato

Akihisa Maeda

Masaru Oogaki

The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity.

Plasminogen activator inhibitor-1 inhibitor

The present invention relates to a novel compound having plasminogen activator inhibitor-1 (PAI-1) inhibitory activity, and a PAI-1 inhibitor comprising the compound as an active ingredient. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. The novel compound is represented by the following general formula. Each symbol is defined as those in the specification.

Inhibitor of plasminogen activator inhibitor-1

The present invention relates to a compound of the formula [I]:  

Cephem compounds

This invention relates to new polypeptide compound represented by the general formula (I) wherein R, R, R, R, Rand Rare as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on &#x3b2;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases includinginfection (e.g.pneumonia) in a human being or an animal.

Cyclic hexapeptide derivatives

This invention relates to new polypeptide compound represented by general formula (I), wherein R, R, R, R, Rand Rare as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on &#x3b2;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases includinginfection (e.g.pneumonia) in a human being or an animal.

Cyclic hexapeptides having antibiotic activity

This invention relates to new polypeptide compounds represented by general formula (I), wherein R,, R,, R,and R,are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on &bgr;-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including,infection (e.g.,pneumonia) in a human being or an animal.

Cyclic hexapeptides with antimicrobial activity

Piperazine derivatives

A piperazine compound of the formula: ##STR1## wherein: X is carbonyl or sulfonyl;

A piperazine compound of the formula: ##STR1## wherein: X is carbonyl or sulfonyl; Y is a direct bond or lower alkylene; and R.sub.1, R.sub.2, R.sub.3, R.sub.4 are as defined herein. The compounds are advantageously used as Tachykinin antagonists in the treatment of respiratory diseases, ophthalmic diseases and inflammatory diseases, for example.

Growing community of inventors

Osaka, Japan

Kenji Murano